Tomahawk, WI 05/27/2014 (Basicsmedia) – Sarepta Therapeutics Inc (NASDAQ:SRPT) expects to get several experimental drugs approved for commercial sales within FY 2015. The company has literally scaled up its capacity and FY 2014 seems to act as a harbinger to a potential rise in demands for its drugs, over a wider gamut.

The $25 Million Deal

Lately, Sarepta Therapeutics Inc (NASDAQ:SRPT) has announced about its propositions for acquiring a suave manufacturing facility located in Massachusetts for a whopping $25 million. The drug makes retracted from disclosing the location of this facility, that shall convert into SRPT’s manufacturing facility in near future.

The whopping price fixed for purchasing the facility includes sumptuous amounts required for renovation and upgradation of the facility. The entire transaction is deemed to be accomplished by the end of July 2014; until then, the company decided to withhold the details pertaining to this facility.

Financial Estimates

On May 8, Sarepta Therapeutics released the Q1-2014 financial results. The company suffered from a net loss of 75 cents/share; however, its gross revenue surged to $6.09 million, soaring up by 36% over the last year’s estimates.

Eteplirsen Gets The Thumb’s Up!

Young men and boys are rarely affected by a devastating disease called Duchenne Muscular Dystrophy that fosters muscle degradation leading to untimely death. The FDA has earlier been skeptical regarding SRPT’s product – Eteplirsen; however, of late, the FDA has wavered the green signal allowing commercial sales of the drug. This boosted activities amongst investors and the stock price shot up, as a consequence. In totality, SRPT has eight therapeutic drugs (including Eteplirsen) in its pipeline. If all get the green signal, SRPT’s stocks would surely veer through, depicting a new acme of success!

The CEO’s Confrontation

Chris Garabedian, CEO and President of Sarepta Therapeutics Inc (NASDAQ:SRPT) stated unequivocally that the company has planned to scale up its capacities to address the expected rising commercial demands of Eteplirsen in the U.S. market. The company is also looking forward to enhance its abilities to procure better development of exon skipping platforms, thus exploring its potential technological parlance in myriad other therapeutic areas; the strategic acquisition is deemed to enhance internal manufacturing capabilities for global supplies of the drugs in the pipeline!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.